Zydus Wellness Limited ZYDUSWELL NIFTY_SMALLNSE
Company Overview
Zydus Wellness Limited engages in the development, production, marketing, and distribution of health and wellness products in Asia, the Middle East, Africa, the Oceania, Europe, and North America. It provides glucose powder under the Glucon-D brand; sugar substitute products under the Sugar Free Gold+, Sugar Free Natura, Sugar Free Green, and I'm lite brands; Milk-based nutrition drink products under the Complan brand; table spreads under the Nutralite brand; skin cleansing products under the Everyuth brand; hair color products under the Cuticolor brand; heat powder under the Nycil brand; and healthy eating products, such as snack bars, protein bars, breakfast cookies, and protein chips under the RiteBite brand. The company also offers plant-based supplements, vitamins and minerals, collagens, omegas, probiotics, and micronutrients for adults under the WeightWorld brand; health and wellness products, including multivitamin and vitamin D3 gummies, mushroom-based supplements, and other superfood supplements under the MaxMedix brand; and food supplements for dogs and cats under the Animigo brand. The company was formerly known as Carnation Nutra-Analogue Foods Limited and changed its name to Zydus Wellness Limited in January 2009. The company was founded in 1988 and is headquartered in Ahmedabad, India. Zydus Wellness Limited operates as a subsidiary of Zydus Lifesciences Limited.
Why Investors Should Care
Revenue has grown at a 20.7% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Mar 2026 Revenue of ₹3,940.00 Cr (+46.4% YoY); net profit ₹197.20 Cr.
- Trailing 12 Months Year-on-year growth — revenue +46.4%, earnings -43.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 20.7%, profit CAGR -14.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 20.67% |
| 1 Year: | 46.40% |
Compounded Profit Growth
| 5 Years: | -14.03% |
| 1 Year: | -43.15% |
Stock Price Performance
| 1 Year: | +37.21% |
| 6 Months: | +39.76% |
| 3 Months: | +4.62% |
| 1 Month: | +0.04% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)51.18 · Neutral
P/E of 85.76 is above the sector median of 23.57 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 20.7% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 85.8.
- Earnings shrank at -14.0% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Consumer Defensive).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ZYDUSWELL Zydus Wellness Limited NIFTY_SMALLNSE | 531.70 | 85.76 | ₹16,916.61 Cr | 0.23% | 3.40% | 3.38% | 20.67% | -14.03% |
| 2 | HINDUNILVR Hindustan Unilever Limited NIFTY50NSE | 1,973.40 | 30.83 | ₹4.64 L Cr | 2.12% | 22.15% | 30.86% | 2.31% | 14.12% |
| 3 | ITC ITC Limited NIFTY50NSE | 264.10 | 16.00 | ₹3.31 L Cr | 5.60% | 36.47% | 28.53% | 3.65% | 2.54% |
| 4 | NESTLEIND Nestlé India Limited NIFTY50NSE | 1,410.50 | 84.82 | ₹2.72 L Cr | 0.78% | 62.44% | 79.99% | 17.01% | 23.05% |
| 5 | DMART Avenue Supermarts Limited NSE | 3,770.00 | 82.62 | ₹2.46 L Cr | 0.00% | 16.41% | 12.14% | 17.14% | 7.69% |
| 6 | VBL Varun Beverages Limited NSE | 407.60 | 45.39 | ₹1.38 L Cr | 0.45% | 19.44% | 15.51% | 17.26% | 26.57% |
| 7 | BRITANNIA Britannia Industries Limited NSE | 5,101.50 | 48.50 | ₹1.23 L Cr | 1.67% | 61.21% | 49.61% | 5.66% | 2.95% |
| 8 | UNITDSPR UNITED SPIRITS LIMITED NSE | 1,471.70 | 56.84 | ₹1.07 L Cr | 1.11% | 25.49% | 20.53% | 5.56% | 17.36% |
| 9 | MARICO Marico Limited NIFTY_MIDNSE | 815.15 | 59.98 | ₹1.06 L Cr | 0.47% | 38.75% | 41.85% | 11.82% | 10.61% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 713.00 Cr | 702.00 Cr | 440.00 Cr | 403.00 Cr | 783.00 Cr | 841.00 Cr | - | 450.80 Cr | 910.60 Cr | 857.70 Cr | 650.00 Cr | 963.30 Cr | 1,476.10 Cr | 1,429.90 Cr |
| Cost of Revenue | - | - | - | - | - | - | - | 235.60 Cr | 411.70 Cr | 387.80 Cr | - | 353.10 Cr | 519.70 Cr | 493.40 Cr |
| Gross Profit | - | - | - | - | - | - | - | 215.20 Cr | 498.90 Cr | 469.90 Cr | - | 610.20 Cr | 956.40 Cr | 936.50 Cr |
| Operating Expenses | 568.00 Cr | 586.00 Cr | 423.00 Cr | 390.00 Cr | 620.00 Cr | 686.00 Cr | - | 205.90 Cr | 321.60 Cr | 325.40 Cr | 628.00 Cr | 605.40 Cr | 746.40 Cr | 751.50 Cr |
| Operating Income | 138.00 Cr | 110.00 Cr | 11.00 Cr | 7.00 Cr | 156.00 Cr | 150.00 Cr | - | 9.30 Cr | 177.30 Cr | 144.50 Cr | -2.00 Cr | 4.80 Cr | 210.00 Cr | 185.00 Cr |
| EBITDA | 145.00 Cr | 116.00 Cr | 17.00 Cr | 13.00 Cr | 162.00 Cr | 155.00 Cr | - | 18.60 Cr | 190.80 Cr | 158.60 Cr | 23.00 Cr | 55.20 Cr | 271.30 Cr | 245.50 Cr |
| Interest Expense | 5.00 Cr | 5.00 Cr | 6.00 Cr | 6.00 Cr | 6.00 Cr | 4.00 Cr | - | 3.30 Cr | 4.20 Cr | 2.50 Cr | 16.00 Cr | 41.20 Cr | 38.70 Cr | 26.30 Cr |
| Pretax Income | 126.00 Cr | 93.00 Cr | 9.00 Cr | 4.00 Cr | 154.00 Cr | 152.00 Cr | - | 10.10 Cr | 173.40 Cr | 145.30 Cr | -51.00 Cr | -41.50 Cr | 177.30 Cr | 162.10 Cr |
| Tax Provision | -18.90 Cr | -16.74 Cr | 2.79 Cr | 3.68 Cr | 4.62 Cr | 4.56 Cr | - | 3.70 Cr | 1.50 Cr | 17.40 Cr | -2.04 Cr | -1.60 Cr | 15.30 Cr | 43.20 Cr |
| Net Income | 145.00 Cr | 110.00 Cr | 6.00 Cr | 0 | 150.00 Cr | 148.00 Cr | - | 6.40 Cr | 171.90 Cr | 127.90 Cr | -53.00 Cr | -39.90 Cr | 162.00 Cr | 118.90 Cr |
| Diluted EPS | 4.57 | 3.47 | 0.19 | 0.01 | 4.72 | 4.64 | - | 0.20 | 5.40 | 4.02 | -1.66 | -1.25 | 5.09 | 3.74 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 431.00 Cr | 397.00 Cr | 431.00 Cr | 513.00 Cr | 843.00 Cr | 1,767.00 Cr | 1,867.00 Cr | - | 2,242.60 Cr | 2,315.20 Cr | 2,691.20 Cr | 3,940.00 Cr |
| Cost of Revenue | - | - | - | - | - | - | - | - | 1,153.00 Cr | 1,146.10 Cr | 1,287.50 Cr | 1,577.20 Cr |
| Gross Profit | - | - | - | - | - | - | - | - | 1,089.60 Cr | 1,169.10 Cr | 1,403.70 Cr | 2,362.80 Cr |
| Operating Expenses | 331.00 Cr | 305.00 Cr | 331.00 Cr | 387.00 Cr | 658.00 Cr | 1,446.00 Cr | 1,522.00 Cr | - | 777.10 Cr | 884.80 Cr | 1,052.70 Cr | 2,007.10 Cr |
| Operating Income | 92.00 Cr | 84.00 Cr | 92.00 Cr | 116.00 Cr | 172.00 Cr | 295.00 Cr | 319.00 Cr | - | 312.50 Cr | 284.30 Cr | 351.00 Cr | 355.70 Cr |
| EBITDA | 100.00 Cr | 91.00 Cr | 99.00 Cr | 125.00 Cr | 185.00 Cr | 321.00 Cr | 344.00 Cr | - | 331.70 Cr | 307.60 Cr | 398.80 Cr | 472.20 Cr |
| Interest Expense | 0 | 0 | 1.00 Cr | 2.00 Cr | 30.00 Cr | 140.00 Cr | 84.00 Cr | - | 15.80 Cr | 23.70 Cr | 11.60 Cr | 95.00 Cr |
| Pretax Income | 120.00 Cr | 117.00 Cr | 124.00 Cr | 150.00 Cr | 171.00 Cr | 121.00 Cr | 112.00 Cr | - | 290.90 Cr | 260.10 Cr | 358.80 Cr | 230.50 Cr |
| Tax Provision | 8.40 Cr | 11.70 Cr | 12.40 Cr | 13.50 Cr | -0 | -20.57 Cr | -6.72 Cr | - | -19.50 Cr | -6.80 Cr | 11.90 Cr | 33.30 Cr |
| Net Income | 111.00 Cr | 105.00 Cr | 111.00 Cr | 137.00 Cr | 171.00 Cr | 142.00 Cr | 119.00 Cr | - | 310.40 Cr | 266.90 Cr | 346.90 Cr | 197.20 Cr |
| Diluted EPS | 5.58 | 5.28 | 5.58 | 6.85 | 5.87 | 4.92 | 3.73 | - | 9.76 | 8.39 | 10.90 | 6.20 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 508.00 Cr | 568.00 Cr | 682.00 Cr | 829.00 Cr | 5,459.00 Cr | 5,590.00 Cr | 5,666.00 Cr | - | 5,833.10 Cr | 6,148.40 Cr | 6,441.90 Cr | 10,307.80 Cr |
| Current Assets | - | - | - | - | - | - | - | - | 907.80 Cr | 1,214.30 Cr | 1,104.20 Cr | 1,366.70 Cr |
| Cash & Equivalents | - | - | - | - | - | - | - | - | 37.00 Cr | 80.00 Cr | 66.70 Cr | 110.60 Cr |
| Inventory | - | - | - | - | - | - | - | - | 457.50 Cr | 467.60 Cr | 517.50 Cr | 763.80 Cr |
| Receivables | - | - | - | - | - | - | - | - | 207.80 Cr | 283.30 Cr | 367.00 Cr | 383.80 Cr |
| Total Liabilities | - | - | - | - | - | - | - | - | 710.50 Cr | 790.90 Cr | 770.30 Cr | 4,481.80 Cr |
| Current Liabilities | - | - | - | - | - | - | - | - | 692.40 Cr | 769.40 Cr | 745.50 Cr | 728.50 Cr |
| Long Term Debt | - | - | - | - | - | - | - | 62.50 Cr | 0 | - | 0 | 3,034.90 Cr |
| Total Debt | 0 | 0 | 25.00 Cr | 25.00 Cr | 1,569.00 Cr | 1,519.00 Cr | 550.00 Cr | - | 297.30 Cr | 328.70 Cr | 188.30 Cr | 3,202.80 Cr |
| Total Equity | 406.00 Cr | 478.00 Cr | 557.00 Cr | 691.00 Cr | 3,387.00 Cr | 3,461.00 Cr | 4,568.00 Cr | - | 5,122.60 Cr | 5,357.50 Cr | 5,671.60 Cr | 5,826.00 Cr |
| Shares Outstanding | - | - | - | - | - | - | - | - | 31.82 Cr | 31.82 Cr | 31.82 Cr | 31.82 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 69.00 Cr | 90.00 Cr | 77.00 Cr | 69.00 Cr | 149.00 Cr | 259.00 Cr | 287.00 Cr | - | 91.70 Cr | 246.40 Cr | 380.00 Cr | 226.40 Cr |
| Investing Cash Flow | 29.00 Cr | -28.00 Cr | -72.00 Cr | -59.00 Cr | -4,092.00 Cr | -17.00 Cr | -10.00 Cr | - | -84.90 Cr | -177.70 Cr | -223.60 Cr | -2,909.90 Cr |
| Financing Cash Flow | -27.00 Cr | -58.00 Cr | -6.00 Cr | -2.00 Cr | 4,052.00 Cr | -260.00 Cr | -216.00 Cr | - | -138.50 Cr | -25.70 Cr | -186.30 Cr | 2,698.40 Cr |
| Capital Expenditure | 3.00 Cr | -4.00 Cr | -31.00 Cr | -8.00 Cr | -17.00 Cr | -24.00 Cr | -18.00 Cr | - | -45.00 Cr | -28.50 Cr | -66.30 Cr | -101.70 Cr |
| Free Cash Flow | 72.00 Cr | 86.00 Cr | 46.00 Cr | 61.00 Cr | 132.00 Cr | 235.00 Cr | 269.00 Cr | - | 46.70 Cr | 217.90 Cr | 313.70 Cr | 124.70 Cr |
| Net Change in Cash | 71.00 Cr | 4.00 Cr | -1.00 Cr | 8.00 Cr | 109.00 Cr | -18.00 Cr | 60.00 Cr | - | -131.70 Cr | 43.00 Cr | -29.90 Cr | 14.90 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | 48.6% | 50.5% | 52.2% | 60.0% |
| Operating Margin % | 21.3% | 21.2% | 21.3% | 22.6% | 20.4% | 16.7% | 17.1% | - | 13.9% | 12.3% | 13.0% | 9.0% |
| Net Margin % | 25.8% | 26.4% | 25.8% | 26.7% | 20.3% | 8.0% | 6.4% | - | 13.8% | 11.5% | 12.9% | 5.0% |
| ROE % | 27.3% | 22.0% | 19.9% | 19.8% | 5.0% | 4.1% | 2.6% | - | 6.1% | 5.0% | 6.1% | 3.4% |
| ROCE % | - | - | - | - | - | - | - | - | 6.1% | 5.3% | 6.2% | 3.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ZYDUSWELL
News by CNBC TV18 on TradingView, 2026-09-07 — cnbctv:567c98873094b:0 - TradingView
<a href="https://news.google.com/rss/articles/CBMiZ0FVX3lxTFBPSEZSN0tDNVNDT3dpS0pMbGk0MVpuMmI4UmpCNnRYdmNGT0VYR3psdkVIUkd2aS15dVJzanB1VUNHOHA5ZUtRVk1wNmt1eDZtVUFmb21qUHZGX19WcV9jNTFKZVVSS0k?oc=5" target="_blank">News by CNBC TV18 on Trading…
News by CNBC TV18 on TradingView, 2026-09-07 — cnbctv:5b8276db5094b:0 - TradingView
<a href="https://news.google.com/rss/articles/CBMiZ0FVX3lxTE1IU0taYmFsR3VkVFBIS3pvRmVRRFhRM0c4akwzLUI1MFliQzJFSF9EZ3EwNlJjTGFZTGZZRmpNNWpuOV9SLVZyTkFpekpPZTFXZDJESWdxU25EU1ctRXFJOXVONGNLdFk?oc=5" target="_blank">News by CNBC TV18 on Trading…
Should You Buy Zydus Wellness Limited (NSE:ZYDUSWELL) For Its Upcoming Dividend? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxQWHUzeVB5TW5Ld3F6N1JMOExpNVBSQzlIU1hEQmhuT05ZbHpEN2dDOVB2aHU2ZXMzMy1LOFNwcnJMMHF3TmN4STBlb1JvbGdQV3FYMnN5LWlnUWthNmwwWW03NGNPQ0w0b3hYS282TnBOSGh1dzY2UlRyOHNPcDBMdC0tc1IzNDZjT1JNQ2…
Zydus Wellness (ZYDUSWELL.NS) Hovers Near Support as Weakness Persists - Watchlist Stock Ideas - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQY3dmQ0JLRXNSNm5nZFVGT0VVUFNsTk13NWJ5aHZnZlk1WGN5eGNLTXNTTi00WV9ncVpPUFlEVDZEaFRHR2FSNGtPUmZpT1NPdWdyTjFFWWlybnpDZExMMWllLThkTENHcExQLTI0SFh0T1RqSWpWZFpjcGhDekpIaFpRdk5LakhRQkJiam…
Zydus Wellness (ZYDUSWELL.NS) Slips 2.65% to ₹496.65: Approaching Key Support Levels - Institutional Flow Picks - siam.in
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxObG41QnhWVHU2ZU5saHlmNF9KQlVBa2lrdnJLWnoySEc2VGx1bk5GNjRBdXdncE9POTE0M1RraFRSTTNTekhvc2NxY3QwTlJTbk5yaFpCUnZuMmR0S1ZrS256UDZLRi10Y29GYkdnd2w5NXVhYXNtV3RQcVMwRDBVUkw4RnE5eDdZYW9NRU…
Zydus Wellness Share Pros and Cons 2026 | ZYDUSWELL Complan Sugar Free - Univest
<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTE5sYnVXWjJTVW92bzdoRE5OWkhUN2tQUlF5eVVmYXJRR3JvUGFlN3Z1SkVzTjVPOGJ1c0tmTksxeHV3N1hRaTZzZWdnMTNEMXRGcVRtS2RHNld0YVN5M05SVkVMUl9xc2VreEotOQ?oc=5" target="_blank">Zydus Wellness Share …
ZYDUSWELL — Frequently Asked Questions
What is the current share price of Zydus Wellness Limited (ZYDUSWELL)?
As of 2026-09-08 04:53 IST, Zydus Wellness Limited (ZYDUSWELL) trades at ₹531.70 on NSE. Its 52-week range is ₹372.76 to ₹602.50.
What is the market capitalisation of ZYDUSWELL?
Zydus Wellness Limited (ZYDUSWELL) has a market capitalisation of ₹16,916.61 Cr on NSE.
What is the P/E ratio of ZYDUSWELL?
ZYDUSWELL trades at a trailing price-to-earnings (P/E) ratio of 85.76. The industry average P/E is 23.57. Its price-to-book (P/B) ratio is 2.92.
Does ZYDUSWELL pay a dividend?
Zydus Wellness Limited (ZYDUSWELL) currently offers a dividend yield of 0.23%.
What is the return on equity (ROE) of ZYDUSWELL?
ZYDUSWELL has a return on equity (ROE) of 3.38%. Its return on capital employed (ROCE) is 3.40%.
Is ZYDUSWELL a good stock to buy?
This page provides a data-driven analysis of Zydus Wellness Limited (ZYDUSWELL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.